ClinicalTrials.gg
RecruitingNCT03973268Updated Nov 17, 2026

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

A Phase 1 interventional study of Arm 1, 2, 3 device interventions and Arm 2 Interventions in Depression, Major Depressive Disorder and Major Depression, sponsored by National Institute of Mental Health (NIMH). Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Institute of Mental Health (NIMH) · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jan 2020; still recruiting 6 years 10 months later.
Updated Nov 10, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in Depression by National Institute of Mental Health (NIMH) — 11 open to participants now, 11 under way, none of them phase 3. Depression · National Institute of Mental Health (NIMH).

Planned enrollment
21st of 50
70 · median 60
Started
2020
with 1 other
Phase 1
13 of 97
4 open now
Registered
87th of 97
by date

Among the 97 studies in Depression by National Institute of Mental Health (NIMH), this one is the 21st largest by planned enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2020, is one of 13 in phase 1, and was the 87th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

11 of the 97 studies in Depression by National Institute of Mental Health (NIMH) are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Depression by National Institute of Mental Health (NIMH), or all of them as a file.
02

Study summary

Background:

Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work. A drug that blocks these receptors might affect how it works.

Objective:

To see if the antidepressant response of ketamine is linked to AMPA receptors.

Eligibility:

Adults ages 18-70 with major depression disorder without psychotic features

Design:

Participants will be screened under protocol 01-M-0254. They will have blood tests and a physical exam.

Participants will stay at the NIH Clinical Center for 5 weeks.

Phase 1 lasts 4 weeks. For 2 weeks, participants will taper off their psychiatric medicine. Then they will have the following tests:

  • Blood draws
  • Psychological tests
  • MRI: Participants will lie in a machine that takes pictures of their brain.
  • MEG: Participants will lie down and do tasks. A cone lowered on their head will record brain activity.
  • Optional sleep tests: Electrodes on the scalp and body and belts around the body will monitor participants while they sleep.
  • Optional TMS: Participants will do tasks while a wire coil is held on their scalp. An electrical current will pass through the coil that affects brain activity.

For phase 2, on day 0 participants will take the study drug or a placebo orally. While having a MEG, they will get ketamine infused into a vein in one arm while blood is drawn from a vein in the other arm. On day 1, participants will again take the study drug or a placebo orally. On days 3-7, they will repeat many of the phase 1 tests. Days 8 and 9 are optional and include an open label ketamine treatment and many of the phase 1 tests.

Read the detailed description

Objective

Work by our group and others has demonstrated that a single intravenous dose of the glutamatergic modulator ketamine consistently produces rapid (within two hours), robust, and relatively sustained (approximately one to two weeks) antidepressant effects in patients with treatment-resistant major depressive disorder (MDD) and bipolar depression. Although ketamine is an N-methyl-D-aspartate (NMDA) receptor (NMDAR) antagonist, convergent evidence from behavioral, cellular, and molecular ketamine studies supports the theory that enhanced -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activity - with a concomitant increase in synaptic plasticity - is critical to its mechanism of antidepressant action and may be the key to developing analogous rapidacting antidepressants. Notably, both animal and human studies indicate that acute, sub-anesthetic ketamine infusion is associated with robust increases in gamma power. Multiple synaptic mechanisms play a role in regulating gamma oscillations, including AMPA receptor (AMPAR)-mediated depolarization and gamma aminobutyric acid (GABA)A receptor-mediated inhibition. Ketamine may influence both of these systems, both by silencing GABAergic inhibitory synapses and by increasing glutamate release, thereby activating AMPARs.

This clinical translational mechanistic protocol, in parallel with a preclinical study (Bench-to-Bedside Award, NIH), is designed to begin to disentangle the neurobiological underpinnings of ketamine's mechanism of antidepressant action and to develop a cross-species biomarker of target engagement (i.e., gamma power). The study will test the importance of AMPAR throughput by attempting to block the behavioral (i.e., antidepressant), electrophysiological, and biochemical effects of ketamine with an AMPAR antagonist. We first demonstrated in animal models that administering an AMPAR antagonist (NBQX) could block ketamine's antidepressant-like properties, suggesting that AMPAR neurotransmission was involved in these effects. This finding has now been replicated by multiple labs. In the present study, we propose to evaluate whether pre-treatment with perampanel, an AMPAR antagonist, blocks or reduces the acute antidepressant effects of ketamine in patients with treatment resistant depression (TRD). Further, we will examine whether AMPAR activity is important to the continued antidepressant effects of ketamine by examining whether treatment with perampanel blocks or reduces ketamine s continued antidepressant effects.

Study Population

70 patients ages 18 to 70 years, with a diagnosis of MDD (without psychotic features) will be recruited for this study.

Study Design

This is a two-phase pathophysiological study that attempts to understand the mechanism of action of ketamine s antidepressant effects. Phase I includes a medication taper, drug-free period, and baseline testing (e.g. clinical rating scales, sEEG, TMS, MEG). In Phase II, participants will receive an open-label ketamine infusion with a randomized, double-blind, add-on intervention (perampanel vs. placebo). Two to three hours prior to receiving ketamine (0.5 mg/kg), subjects will be randomized into one of three arms. Subjects in Arm 1 will receive perampanel (8 mg p.o.), while those randomized to Arm 2 or Arm 3 will receive matching placebo. On Day 1, the second blinded oral medication will be administered after clinical rating scales are obtained. Subjects randomized to Arm 1 and 3 will receive matching placebo, while subjects randomized to Arm 2 will receive perampanel. sEEG, TMS, and MEG will be obtained again on two more occasions during Phase II. Participants who completed Phase II will also be offered one open-label ketamine treatment, during which they will be assessed for mood symptoms and possible side effects.

Outcome Measures

The primary outcome measure is the Montgomery-Asberg Depression Rating Scale (MADRS). Hypothesis 1: By Day 1, patients treated with ketamine who are randomized to pre-treatment with a single oral dose of the AMPAR antagonist perampanel will have significantly more depressive symptoms than those who are randomized to pretreatment with placebo, as measured by the MADRS. Hypothesis 2: By Day 2, patients treated with ketamine who were randomized to perampanel on Day 1 will have significantly more depressive symptoms than those who were randomized to placebo, as measured by the MADRS. To acquire data corroborating that ketamine s antidepressant effects are mediated through AMPARs, surrogate plasticity measures will be obtained using sEEG, TMS, and MEG. In addition, blood samples for biomarkers will also be obtained.

03

Conditions studied

  • Depression
  • Major Depressive Disorder
  • Major Depression

Keywords

  • Biomarker
  • AMPA Antagonist
  • Magnetoencephalography
  • Neuropharmacology
  • Neurobiology
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phases I-II

  1. 18 to 70 years of age.
  2. Each subject must have a level of understanding sufficient to agree to all required tests and examinations and sign an document.
  3. All subjects must have undergone a screening assessment under protocol 01-M-0254, "The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers".
  4. Subjects must fulfill or -5criteria for Major Depression (Major Depressive Disorder) without psychotic features, based on clinical assessment and informed by a structured diagnostic interview (SCID-P).
  5. Subjects must have an initial score on the MADRS >= 22 and a YMRS score of \<12 within one week of study entry and upon entry into Phase II.
  6. Lack of response to two adequate antidepressant trials, with [at least] one in the current major depressive episode, operationally defined using the Antidepressant Treatment History Form (ATHF); a failed adequate trial of ECT [or TMS] would count as an adequate antidepressant trial.
  7. Current major depressive episode lasting at least four weeks
  8. Agree to be hospitalized

Open-Label Ketamine Treatment

  1. Participants must have met all inclusion criteria for and completed Study Phase II
  2. Individuals who are able to get pregnant must be willing to remain sexually abstinent or use at least one form of effective during participation in Phase III.

Exclusion criteria

EXCLUSION CRITERIA:

Phases I-II

  1. Current psychotic features or a diagnosis of schizophrenia or any other psychotic disorder as defined in the or DSM-5.
  2. Subjects with a history of substance abuse or dependence diagnosis (DSM-IV) or substance use disorder (DSM-5 equivalent) (except for caffeine or nicotine dependence) within the preceding 3 months. In addition, subjects who currently are using drugs (except for caffeine or nicotine) must not have used illicit substances or known drugs of abuse in the 2 weeks prior to screening and must have a negative alcohol and drug urine test (except for prescribed benzodiazepines or stimulants) at screening.
  3. Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease, coronary artery disease, atherosclerotic ischemic stroke, and atrial fibrillation), endocrinologic, neurologic, immunologic, or hematologic disease.
  4. Pregnant or nursing individuals or those who are physically able to become pregnant. Participants who are physically able to become pregnant or cause a pregnancy must use at least one form of effective or remain completely abstinent from sexual intercourse during the entire period of study participation (or until the last clinical labs and ratings). Participants able to become pregnant must have negative urine pregnancy tests no more than 24 hours prior to receiving the study drugs and undergoing imaging procedures.
  5. Subjects with one or more seizures without a clear and resolved etiology or current use of medication known to lower seizure threshold. History of seizure (regardless of age or etiology), history of epilepsy in self or first-degree relatives, stroke, brain surgery, head injury, or known structural brain lesion will be excluded from the TMS procedures.
  6. Presence of any medical illness likely to alter brain morphology and/or physiology (e.g., hypertension, diabetes) even if controlled by medications.
  7. abnormal laboratory tests.
  8. (For imaging procedures) Subjects with hearing loss that has been clinically evaluated and diagnosed and may be worsened through participation in imaging procedures
  9. Positive test
  10. Weight > 119 kg
  11. Treatment with any concomitant psychiatric medication prior to entering Phase II. [Medications must be tapered during Phase I.]
  12. Treatment with any non-psychiatric medication/s.
  13. Any use of opioid medication in the past 3 months
  14. Treatment with a reversible monoamine oxidase inhibitor (MAOI) prior to entering Phase II. [Medications must be tapered during Phase I.]
  15. Treatment with fluoxetine or aripiprazole at the time of screening.
  16. Unwilling to stop undergoing structured, individualized psychotherapy. (Such therapy, including CBT, will not be permitted during Phases I and II of the study.)
  17. Presence of metallic (ferromagnetic) implants (e.g., heart pacemaker, aneurysm clip).
  18. Participants who are uncomfortable in small closed spaces (have claustrophobia).
  19. Are unable to lie comfortably supine for up to 90 minutes and would feel uncomfortable in the MRI and MEG machines.
  20. Subjects who, in the investigator s judgment, pose a current serious suicidal or homicidal risk.
  21. Subjects who have a history of aggressive behavior towards others

Open-Label Ketamine Treatment

  1. Intolerable or serious adverse reaction to ketamine during Phase II
  2. Participants with a positive urine for an illicit substance no more than 24 hours prior to ketamine treatment.
  3. Pregnant or nursing individuals or those who plan to become pregnant.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    1

    Individuals in Arm 1 will receive double-blinded perampanel and open-label ketamine on the first day, then double-blinded perampanel on the second day.

    Device: Arm 1, 2, 3 device interventions · Drug: Arm 1, 2, 3 drug Interventions · Drug: Arm 1 and 2 Interventions

  • Experimental
    2

    Individuals in Arm 2 will receive double-blinded placebo and open-label ketamine on the first day, then double-blinded perampanel on the second day.

    Device: Arm 1, 2, 3 device interventions · Other: Arm 2 Interventions · Drug: Arm 1, 2, 3 drug Interventions · Drug: Arm 1 and 2 Interventions

  • Experimental
    3

    Individuals in Arm 3 will receive double-blinded placebo and open-label ketamine on the first day, then double-blinded placebo on the second day.

    Device: Arm 1, 2, 3 device interventions · Drug: Arm 1 and 2 Interventions

Interventions

  • DeviceArm 1, 2, 3 device interventions

    MagPro 100 TMS Therapy System

  • OtherArm 2 Interventions

    Placebo

  • DrugArm 1, 2, 3 drug Interventions

    Ketamine

  • DrugArm 1 and 2 Interventions

    Perampanel

06

What researchers measure

Primary outcomes

  1. Acute Antidepressant Efficacy: Change from baseline Montgomery Asberg Depression Rating Scale (MADRS) score post ketamine infusion

    Clinical rating scale of depression

    Time frame: Baseline, Day 1

  2. Continued Antidepressant Efficacy: Change from baseline MADRS score post treatment with ketamine with perampanel versus placebo.

    Clinical rating scale of depression

    Time frame: Baseline, Day 1, Day 2 Day 7

Secondary outcomes

  1. Acute Antidepressant Efficacy: Change in slow wave activity/slope post ketamine infusion

    Polysomnography (PSG)/Electroencephalography (EEG) data

    Time frame: Baseline (night), Day 1 (night)

  2. Acute Antidepressant Efficacy: Change in synaptic plasticity post ketamine infusion

    Transcranial Magnetic Stimulation (TMS) data

    Time frame: Baseline, Day 1

  3. Continued Antidepressant Efficacy: Gamma power change from baseline post treatment with ketamine with perampanel versus placebo

    Magnetoencephalography (MEG) data

    Time frame: Baseline, Day 1

  4. Continued Antidepressant Efficacy: Change in slow wave activity/slope from baseline post treatment with ketamine with perampanel versus placebo

    PSG/EEG data

    Time frame: Baseline (night), Day 1 (night)

  5. Continued Antidepressant Efficacy: Change in synaptic plasticity from baseline post treatment with ketamine with perampanel versus placebo

    TMS data

    Time frame: Baseline, Day 1

  6. Acute Antidepressant Efficacy: Gamma power change from baseline post ketamine infusion

    Magnetoencephalography (MEG) data

    Time frame: Baseline, Day 1

  7. Acute Antidepressant Efficacy: Change in peripheral measures associated with the administration of ketamine

    Plasma/serum biomarkers

    Time frame: Baseline, Day 1, Day 2, Day 7

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • NIH Clinical Center Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Individual participant data

Plan to share: Yes — Clinical and demographic and biomarker participant data collected during the trial, after deidentification.

Supporting information: Statistical analysis plan

Time frame: Starting within 1 year of completion of the study.

Access criteria: The Branch Chief will review requests and access will need to be approved by the NIMH/DIRP SD and OCD NIMH and the NIH IIRB.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Feb 2027, 84 months after the start.

Of 82 non-industry phase 1 interventional studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 61. This study's planned 84 months is above that.

Counting every sponsor, half of 102 studies reached it within 27 months; a quarter within 11 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2019
First posted
Jun 4, 2019
StartActual
Jan 21, 2020
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited; 1 exclusion criterion removed
What changed in the criteria
Inclusion criteria
  • EditedSubjects must have an initial score on the MADRS greater than or equal to>= 22 and a YMRS score of <12 within one week of study entry and upon entry into Phase II.
Exclusion criteria
  • RemovedA current NIMH employee/staff or their immediate family member
Nov 10, 2026
Show all 4 updates
  1. Nov 17, 2026
    Minor edits only
    + 1 other change: verification date
  2. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date
  3. Nov 10, 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion removed
    What changed in the criteria
    Inclusion criteria
    • EditedSubjects must have an initial score on the MADRS greater than or equal to>= 22 and a YMRS score of <12 within one week of study entry and upon entry into Phase II.
    Exclusion criteria
    • RemovedA current NIMH employee/staff or their immediate family member
    + 1 other change: description
  4. Oct 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03973268
Responsible party
Sponsor
First posted
Jun 4, 2019
Start date
Jan 21, 2020
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Yamila I Carmona
Contact
yamila.carmona@nih.gov
(301) 256-8971
Carlos A Zarate, M.D.
principal investigator · National Institute of Mental Health (NIMH)

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion